ISSN: 0970-938X (Print) | 0976-1683 (Electronic)
An International Journal of Medical Sciences
Objective: This study aims to investigate the effect of rosuvastatin combined with trimetazidine in the treatment of patients with coronary heart disease.
Methods: Fifty-five cases of patients with coronary heart disease who were admitted in our department and underwent rosuvastatin therapy from December 2013 to February 2017 were selected as the control group. Another 55 cases of patients with coronary heart disease undergoing rosuvastatin combined with trimetazidine were designated as the observation group. The cardiac function indexes were analysed after the treatment.
Results: The cardiac function indexes of patients in the two groups showed significant difference after the treatment between the observation group and the control group (P<0.05). Blood lipid indexes (TC, TG, HDL-C, and LDL-C) showed no significant difference before the treatment (P>0.05). After the treatment, TC and LDL-C of patients in the observation group were significantly lower than that before the treatment. In comparison with the control group, a significant difference (P<0.05) was observed. In the observation group, the readmission rate of myocardial infarction or angina was 9.1%, which is 23.6% lower than that in the control group; a significant difference (P<0.05) was observed.
Conclusion: Rosuvastatin combined with trimetazidine therapy can improve heart function and enhance the curative effect of patients with coronary heart disease. Therefore, this combination can potentially be applied in the treatment of this disease.Author(s): Yong-Zhong Mao, Ling Jiang